Abstract
Summary
The global Carrier Screening Market is expected to reach USD 5.4 Billion by 2028 from USD 2.2 Billion in 2023, at a CAGR of 19.7% during the forecast period. Market is driven by factors such as Ongoing advancements in genetic testing technologies, such as next-generation sequencing (NGS), improve the efficiency, accuracy, and cost-effectiveness of carrier screening, The increasing prevalence of genetic disorders, coupled with a greater understanding of the genetic basis of various conditions On the other hand, The demand for genetic counseling services often exceeds the available resources. A shortage of genetic counselors can hinder the delivery of comprehensive counseling to individuals undergoing carrier screening, potentially limiting the understanding and interpretation of results.
“The Neurological Conditions accounted for the second largest market share in the carrier screening market product’ s market, during the forecast period”
Based on the Medical Conditions, Carrier Screening Market is classified into Hematologic Conditions, Pulmonary Conditions, Neurological Conditions, and Others. In 2022, Neurological Conditions accounted for a sizable market share because Many neurological disorders have a genetic component. Understanding the genetic basis of conditions such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and certain forms of epilepsy can be crucial for assessing the risk of passing on these conditions to future generations. Likewise, Carrier screening for neurological conditions allows for early detection of genetic risk factors. Early identification of carriers provides an opportunity for individuals and couples to make informed reproductive decisions and consider interventions or therapies early in the planning stages.
“PCR technology segment accounted for the second largest market share”
Based on type on technology, the carrier screening market is segmented into DNA Sequencing, PCR, DNA Microarray, and Other. The PCR technology segment accounted for the second largest market share in 2022., due to its variety of applications such as PCR technology is known for its high sensitivity and specificity in amplifying and detecting specific DNA sequences. This accuracy is crucial in carrier screening to reliably identify carriers of genetic mutations associated with various disorders, likewise, PCR allows for the amplification of multiple target DNA sequences in a single reaction, a feature known as multiplexing. This capability is valuable in carrier screening,
“APAC region accounted for the third highest CAGR”
The global Carrier Screening market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a considerable market share in 2022 and the future. The Asia-Pacific market is being propelled by an rising cases of rare disease, rising in healthcare expenditure, rising in awareness about early disease diagnosis.
“Europe is estimated to register the second highest CAGR during the forecast period.”
In this report, the Carrier Screening market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the second highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of genetic and rare diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies such as carrier screening.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
• By Designation: C-level - 30%, D-level - 34%, and Others - 36%
• By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World – 12%
Lits of Companies Profiled in the Report:
Invitae Corporation. (US)
Fulgent Genetics.(US)
Eurofins Scientific (Germany)
OPKO Health, Inc.(US)
Thermo Fisher Scientific Inc.(US)
Quest Diagnostics Incorporated (US)
Myriad Genetics, Inc (US)
Illumina, Inc.(US)
Natera, Inc.(Italy)
Laboratory Corporation of America Holdings.(US)
CENTOGENE N.V.(Germany)
DiaSorin S.p.A.(Italy)
BGI (China)
Otogenetics (US)
GeneTech (India)
Signature Diagnostics Inc.(US)
MedGenome (US)
Ambry Genetics.(US)
Asper Biogene (Estonia)
LifeLabs Genetics (Canada)
EasyDNA (US)
LifeCell (India)
CNC Path Lab (India)
Oxy-Gen Laboratory LLC (US)
Mitera (US)
Research Coverage:
This report studies the Carrier Screening market based on Product & Service, Type, Medical Condition, Technology, End User, and Region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Carrier Screening market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.
Market Penetration: Comprehensive information on Carrier Screening Market products offered by the top 25 players in the market. The report analyses the Carrier Screening market by Product & Service, Type, Medical Condition, Technology, End User, and Region.
Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.
Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Carrier Screening market
Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Carrier Screening market
Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 INCLUSIONS & EXCLUSIONS 32
1.4 MARKET SCOPE 33
1.4.1 MARKETS COVERED 33
1.4.2 REGIONS COVERED 33
1.4.3 YEARS CONSIDERED 34
1.4.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 34
1.6 SUMMARY OF CHANGES 35
1.6.1 RECESSION IMPACT: CARRIER SCREENING MARKET 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
2.1.1 SECONDARY DATA 36
2.1.2 PRIMARY DATA 39
- 2.1.2.1 Key data from primary sources 39
- 2.1.2.2 Key industry insights 40
- 2.1.2.3 Breakdown of primary interviews 41
2.2 MARKET ESTIMATION 41
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 42
2.2.2 GROWTH FORECAST 44
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 46
2.4 RESEARCH LIMITATIONS 47
2.5 MARKET SHARE ANALYSIS 47
2.6 STUDY ASSUMPTIONS 47
2.7 RISK ASSESSMENT 48
2.8 IMPACT OF ECONOMIC RECESSION ON CARRIER SCREENING MARKET 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 55
4.1 CARRIER SCREENING MARKET OVERVIEW 55
4.2 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2023-2028 55
4.3 NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2023 56
4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: CARRIER SCREENING MARKET 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 58
- 5.2.1.1 Increasing emphasis on early disease detection and prevention 58
- 5.2.1.2 Growing prevalence of genetic disorders 58
- 5.2.1.3 High risk of chromosomal abnormalities with advancing maternal age 59
- 5.2.1.4 Increased focus on preconception and prenatal testing 59
- 5.2.1.5 Rising number of fertility clinics and IVF centers 60
- 5.2.1.6 Declining rate of fertility 60
5.2.2 RESTRAINTS 61
- 5.2.2.1 Ethical concerns in preconception genetic carrier screening 61
- 5.2.2.2 High cost of carrier screening 62
5.2.3 OPPORTUNITIES 62
- 5.2.3.1 Increased awareness about reproductive health in emerging economies 62
- 5.2.3.2 Integration with telehealth and digital health platforms 63
- 5.2.3.3 Increased number of collaborations and partnerships among healthcare organizations 64
- 5.2.3.4 Increasing number of government initiatives and policies toward genetic health improvement 64
- 5.2.3.5 Growing focus on health screening for rare diseases 65
5.2.4 CHALLENGES 65
- 5.2.4.1 Lack of skilled professionals 65
- 5.2.4.2 Lack of standard guidelines for carrier screening 65
5.3 TRENDS 66
5.3.1 LACK OF PUBLIC INTEREST IN EXPANDED CARRIER SCREENING 66
5.4 PRICING ANALYSIS 66
5.5 VALUE CHAIN ANALYSIS 67
5.6 SUPPLY CHAIN ANALYSIS 68
5.7 PORTER’S FIVE FORCES ANALYSIS 69
5.7.1 THREAT OF NEW ENTRANTS 69
5.7.2 THREAT OF SUBSTITUTES 70
5.7.3 BARGAINING POWER OF SUPPLIERS 70
5.7.4 BARGAINING POWER OF BUYERS 70
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.8 ECOSYSTEM/MARKET MAP 71
5.9 TARIFF & REGULATORY LANDSCAPE 72
5.9.1 NORTH AMERICA 73
- 5.9.1.1 US 73
- 5.9.1.2 Canada 73
5.9.2 EUROPE 73
- 5.9.2.1 UK 73
- 5.9.2.2 France 73
5.9.3 ASIA PACIFIC 74
- 5.9.3.1 Japan 74
- 5.9.3.2 India 74
5.10 PATENT ANALYSIS 74
5.10.1 PATENT TRENDS FOR CARRIER SCREENING 74
5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS 75
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
5.11.1 REVENUE SHIFT AND REVENUE POCKETS FOR CARRIER SCREENING MANUFACTURERS 75
5.12 KEY CONFERENCES & EVENTS 76
5.13 TECHNOLOGY ANALYSIS 77
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 78
5.14.1 KEY STAKEHOLDERS 78
5.14.2 BUYING CRITERIA 78
5.15 TRADE ANALYSIS 79
6 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE 80
6.1 INTRODUCTION 81
6.2 SERVICES 81
6.2.1 RISING NUMBER OF ACCREDITED LABORATORIES AND GENETIC CASES TO DRIVE MARKET 81
6.3 PRODUCTS 82
6.3.1 GROWING INCIDENCE OF CHROMOSOMAL ABNORMALITIES AND RISING USE OF CARRIER SCREENING TESTS TO DRIVE MARKET 82
7 CARRIER SCREENING MARKET, BY TYPE 84
7.1 INTRODUCTION 85
7.2 EXPANDED CARRIER SCREENING 85
7.2.1 PREDESIGNED PANEL TESTING 86
- 7.2.1.1 Predesigned panel testing segment to command larger market share during forecast period 86
7.2.2 CUSTOMIZED PANEL TESTING 88
- 7.2.2.1 Better customization options for meeting specific customer requirements to drive segment 88
7.3 TARGETED DISEASE CARRIER SCREENING 89
7.3.1 INTRODUCTION OF PANELS FOR SIMULTANEOUSLY SCREENING MULTIPLE GENETIC CONDITIONS TO DRIVE MARKET 89
8 CARRIER SCREENING MARKET, BY MEDICAL CONDITION 90
8.1 INTRODUCTION 91
8.2 PULMONARY CONDITIONS 91
8.2.1 INCREASING AWARENESS ABOUT CYSTIC FIBROSIS IN REPRODUCTIVE PLANNING TO DRIVE MARKET 91
8.3 HEMATOLOGICAL CONDITIONS 93
8.3.1 RISING PREVALENCE OF HEMATOLOGICAL DISORDERS AMONG INFANTS TO DRIVE MARKET 93
8.4 NEUROLOGICAL CONDITIONS 94
8.4.1 INCREASED AWARENESS OF NEUROLOGICAL SCREENING AND PRESENCE OF TARGETED SCREENING PANELS TO DRIVE MARKET 94
8.5 OTHER MEDICAL CONDITIONS 96
9 CARRIER SCREENING MARKET, BY TECHNOLOGY 98
9.1 INTRODUCTION 99
9.2 DNA SEQUENCING 99
9.2.1 DNA SEQUENCING SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD 99
9.3 PCR 101
9.3.1 HIGH ACCURACY, LOW REACTION TIME, AND ABSOLUTE ESTIMATION OF TARGET MOLECULE TO DRIVE MARKET 101
9.4 DNA MICROARRAYS 102
9.4.1 ABILITY TO ANALYZE MULTIPLE GENETIC MARKERS IN SINGLE ASSAY TO DRIVE MARKET 102
9.5 OTHER TECHNOLOGIES 103
10 CARRIER SCREENING MARKET, BY END USER 104
10.1 INTRODUCTION 105
10.2 HOSPITALS AND MEDICAL CENTERS 105
10.2.1 RISING PATIENT POPULATION AND INCREASING MEDICARE REIMBURSEMENT FOR CLINICAL TESTS TO DRIVE SEGMENT 105
10.3 CLINICAL LABORATORIES 106
10.3.1 LOWER SERVICE COSTS AND HIGHER TURNAROUND TIME TO DRIVE MARKET 106
10.4 FERTILITY CLINICS 107
10.4.1 INCREASING NUMBER OF INFERTILE COUPLES AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES TO DRIVE MARKET 107
10.5 OTHER END USERS 108
11 CARRIER SCREENING MARKET, BY REGION 110
11.1 INTRODUCTION 111
11.2 NORTH AMERICA 111
11.2.1 NORTH AMERICA: RECESSION IMPACT 115
11.2.2 US 116
- 11.2.2.1 Increasing number of genetic diseases and rising healthcare expenditure to drive market 116
11.2.3 CANADA 119
- 11.2.3.1 Increasing government and non-government funding to drive market 119
11.3 EUROPE 123
11.3.1 EUROPE: RECESSION IMPACT 124
11.3.2 GERMANY 127
- 11.3.2.1 Increasing number of government initiatives and healthcare expenditures to drive market 127
11.3.3 UK 130
- 11.3.3.1 Rising prevalence of hematological disease and increasing number of accredited clinical laboratories to drive market 130
11.3.4 FRANCE 133
- 11.3.4.1 Better healthcare infrastructure and higher expenditure for life science research to drive market 133
11.3.5 ITALY 136
- 11.3.5.1 Growing prevalence of chronic diseases and rising number of hospitals to drive market 136
11.3.6 SPAIN 139
- 11.3.6.1 Increasing prevalence of rare genetic diseases and rising availability of research funding to drive market 139
11.3.7 REST OF EUROPE 141
11.4 ASIA PACIFIC 144
11.4.1 ASIA PACIFIC: RECESSION IMPACT 145
11.4.2 INDIA 148
- 11.4.2.1 Growing incidence of rare diseases and declining fertility rates to drive market 148
11.4.3 CHINA 151
- 11.4.3.1 Rising focus on vaccine development and cancer research to drive market 151
11.4.4 JAPAN 154
- 11.4.4.1 Rising geriatric population and growing government healthcare expenditure to drive market 154
11.4.5 REST OF ASIA PACIFIC 158
11.5 REST OF THE WORLD 161
11.5.1 REST OF THE WORLD: RECESSION IMPACT 162
11.5.2 LATIN AMERICA 164
- 11.5.2.1 Higher prevalence of genetic disorders and growing focus on reproductive healthcare services to drive market 164
11.5.3 MIDDLE EAST & AFRICA 167
- 11.5.3.1 GCC Countries 170
- 11.5.3.1.1 Improved healthcare infrastructure and launch of genome projects to drive market 170
- 11.5.3.1 GCC Countries 170
12 COMPETITIVE LANDSCAPE 174
12.1 OVERVIEW 174
12.2 KEY STRATEGIES/RIGHT TO WIN 174
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 174
12.3 MARKET SHARE ANALYSIS 175
12.4 REVENUE SHARE ANALYSIS 175
12.5 COMPANY EVALUATION MATRIX 177
12.5.1 STARS 177
12.5.2 EMERGING LEADERS 177
12.5.3 PERVASIVE PLAYERS 177
12.5.4 PARTICIPANTS 177
12.5.5 COMPANY FOOTPRINT 178
12.6 START-UP/SME EVALUATION MATRIX 181
12.6.1 PROGRESSIVE COMPANIES 181
12.6.2 RESPONSIVE COMPANIES 181
12.6.3 DYNAMIC COMPANIES 181
12.6.4 STARTING BLOCKS 182
12.6.5 COMPETITIVE BENCHMARKING 182
12.7 COMPETITIVE SCENARIOS AND TRENDS 183
12.7.1 KEY DEALS 183
13 COMPANY PROFILES 184
13.1 KEY PLAYERS 184
13.1.1 NATERA, INC 184
13.1.2 QUEST DIAGNOSTICS INCORPORATED 187
13.1.3 FULGENT GENETICS 189
13.1.4 INVITAE CORPORATION 192
13.1.5 EUROFINS SCIENTIFIC 195
13.1.6 OPKO HEALTH, INC 197
13.1.7 THERMO FISHER SCIENTIFIC INC 200
13.1.8 MYRIAD GENETICS, INC 202
13.1.9 ILLUMINA, INC 204
13.1.10 LABORATORY CORPORATION OF AMERICA HOLDINGS 206
13.1.11 CENTOGENE N.V 209
13.1.12 DIASORIN S.P.A 211
13.1.13 BGI 213
13.1.14 OTOGENETICS 214
13.1.15 GENETECH 215
13.2 OTHER PLAYERS 216
13.2.1 OXY-GEN LABORATORY LLC 216
13.2.2 MEDGENOME 217
13.2.3 AMBRY GENETICS 218
13.2.4 ASPER BIOGENE 219
13.2.5 LIFELABS GENETICS 220
13.2.6 EASYDNA 221
13.2.7 LIFECELL 222
13.2.8 CNC PATH LAB 223
13.2.9 SIGNATURE DIAGNOSTICS INC 224
13.2.10 MITERA 225
14 APPENDIX 226
14.1 DISCUSSION GUIDE 226
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
14.3 CUSTOMIZATION OPTIONS 231
14.4 RELATED REPORTS 231
14.5 AUTHOR DETAILS 232